157 related articles for article (PubMed ID: 15277309)
1. PET studies and physiopathology of motor fluctuations in Parkinson's disease.
Linazasoro G; Leenders KL
Brain; 2004 Aug; 127(Pt 8):E15; author reply E16. PubMed ID: 15277309
[No Abstract] [Full Text] [Related]
2. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
[No Abstract] [Full Text] [Related]
4. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
5. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
[No Abstract] [Full Text] [Related]
6. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Djamshidian A; Poewe W
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Nutt JG; Carter JH
Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
[TBL] [Abstract][Full Text] [Related]
9. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Parkinson disease in patients with surgical problems].
Sobolewski P
Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
[TBL] [Abstract][Full Text] [Related]
11. Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.
Brooks DJ
Wien Klin Wochenschr; 2006 Oct; 118(19-20):570-2. PubMed ID: 17136330
[No Abstract] [Full Text] [Related]
12. The modern management of Parkinson's disease.
Quinn N
J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):93-5. PubMed ID: 2107279
[No Abstract] [Full Text] [Related]
13. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
Priano L; Albani G; Brioschi A; Guastamacchia G; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2003 Oct; 24(3):207-8. PubMed ID: 14598090
[TBL] [Abstract][Full Text] [Related]
14. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
15. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
16. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
[TBL] [Abstract][Full Text] [Related]
17. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
Lieberman A; Le Brun Y; Boal D; Zolfaghari M
Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
[No Abstract] [Full Text] [Related]
18. Levodopa and the progression of Parkinson's disease.
Walton-Hadlock JL
N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
[No Abstract] [Full Text] [Related]
19. Apomorphine in the treatment of Parkinson's disease.
Menon R; Stacy M
Expert Opin Pharmacother; 2007 Aug; 8(12):1941-50. PubMed ID: 17696795
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
